Acute coronary syndrome
Conditions
Interventions
Treatment Group:Statins + Ezetimibe + PCSK9 inhibitor
Sponsors
the First Affiliated Hospital, Sun Yat-Sen University
Eligibility
Sex/Gender
All
Age
18 Years to 79 Years
Inclusion criteria
Inclusion criteria: 1. >=18 years old, regardless of gender; 2. Diagnosed with acute coronary syndrome (including ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction or unstable angina pectoris), and within 72 hours of onset; 3. The presence of dyslipidemia (LDL-c level > 2.6 mmol/l); 4. MR angiography of cervical vessels (limited carotid artery intima-media thickness >=2.0mm); 5. Has signed the informed consent for the study.
Exclusion criteria
Exclusion criteria: 1. Cardiogenic shock or require inotropic drugs or intra-aortic balloon counterpulsation (IABP) support; 2. Uncorrected circulatory congestion or valvular heart disease is expected to be frequently hospitalized or developed during follow-up; 3. In the acute exacerbation period of heart failure, unable to cooperate with lying down for a long time; 4. Have a history of hepatitis B or C; 5. The elevation of ALT is more than 3 times higher than the normal high value or the total bilirubin is more than 2 times higher than the normal high value; 6. Patients with pacemaker installed; 7. There are other causes of angina pectoris: such as severe aortic valve stenosis or insufficiency, coronary inflammation caused by rheumatic fever or other causes, coronary stenosis or occlusion caused by syphilitic aortitis, hypertrophic cardiomyopathy, congenital coronary anomalies; 8. Other serious cardiovascular and cerebrovascular events, such as stroke or transient ischemic attack, have occurred in the last three months; 9. Suffering from malignant tumors, multiple organ failure and other diseases that lead to short survival, and the expected life expectancy does not exceed 2 months; 10. Suffering from cognitive dysfunction, substance dependence, severe mental illness; 11. Intravenous drug addicts; 12. Pregnant or breastfeeding women, or planning to become pregnant or donate eggs during the study period; 13. Failure to cooperate with follow-up; 14. Participate in any other clinical trials at the same time; 15. Unable to understand or cooperate with all follow-ups; 16. Any other factors that may reduce compliance with the trial protocol; 17. The investigator believes that it is not suitable to participate in this clinical trial for any reason.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Carotid plaque fibrous cap thickness; | — |
Secondary
| Measure | Time frame |
|---|---|
| Plaque calcification score;Incidence of bleeding in the plaque;Number of lipid necrotic cores;Lumen stenosis degree;Serum LDL-c concentration;Heart systolic and diastolic function;6 minutes walking distance;Non-invasive cardiac output testing related indicators of cardiac function; | — |
Countries
China
Contacts
Public ContactLiu Chen
The First Affiliated Hospital, Sun Yat-Sen University
Outcome results
None listed